Aligos Therapeutics, Inc. (ALGS)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue from customers | 965 | - | 19 | |
| Research and development | 13,976 | 14,502 | 16,774 | |
| General and administrative | 5,556 | 5,052 | 4,626 | |
| Total operating expenses | 19,532 | 19,554 | 21,400 | |
| Revenue from customers | - | 311 | 1,250 | |
| Loss from operations | -18,567 | -19,243 | -20,131 | |
| Change in fair value of 2023 common warrants | -1,682 | -61,494 | - | |
| Interest and other income, net | 1,207 | 880 | 963 | |
| (loss) income before income tax | -15,678 | 43,131 | -19,168 | |
| Income tax provision | 185 | 43 | 91 | |
| Net (loss) income | -15,863 | 43,088 | -19,259 | |
| Unrealized (loss) gain on available-for-sale securities | -27 | -4 | 83 | |
| Other comprehensive (loss) gain | -27 | -4 | 83 | |
| Comprehensive (loss) income | -15,890 | 43,084 | -19,176 | |
| Earnings per share, basic, total | -1.53 | 5.12 | -3.07 | |
| Earnings per share, diluted, total | -1.53 | -2.11 | -3.07 | |
| Weighted average number of shares outstanding, basic, total | 10,351,120 | 8,408,481 | 6,272,291 | |
| Weighted average shares of common stock, diluted | 10,351,120 | 8,709,693 | 6,272,291 | |